The role of leptin in patients recovering from Anorexia Nervosa
DOI:
https://doi.org/10.2478/cpp-2021-0013Keywords:
anorexia nervosa, eating disorders, leptin, adipokinesAbstract
Introduction: Anorexia nervosa (AN) is a mental disorder with the highest death rate. The characteristic feature of AN is endocrine dysregulations, including changes in adipose-tissue secreted hormones, especially adipokines. The most widely studied of them is leptin whose role in the pathophysiology and prognosis of AN is confirmed in more and more studies. The aim of the study was to summarize the role of endocrine disruptions with particular emphasis on leptin in the pathophysiology of AN.
Material and methods: For the literature review, the electronic databases PubMed, Cochrane and Google Scholar search were used with the following keywords: eating disorders, adipokines, leptin, metreleptin, satiety, hunger, anorexia, obesity, for studies listed from database inception to October 2021.
Results: Leptin, produced mainly by white adipose tissue, inhibits the hunger center in the hypothalamus by negative feedback with ghrelin secreted by the gastrointestinal tract. Leptin is involved in numerous biological functions, including body weight regulation, innate and adaptive immunity regulation, reproduction, and bone formation. Studies confirm decreased leptin levels in AN individuals. In recent years, extensive experience has been gained with leptin as a drug in clinical trials. The studies suggested that treatment can restore menstrual function and bone health and improve mood with unclear body weight effects.
Conclusions: Focusing on leptin-related changes is a promising approach to improve AN management. Assessment of leptin levels in AN patients could be a useful tool for therapy monitoring. Treatment with leptin could reverse unfavourable changes induced by diet restriction, including mood symptoms, loss of bone mass and menstrual function. However, the results of these studies need confirmation on larger groups of patients.
References
1. Morris J., Twaddle S. Anorexia nervosa. BMJ. 2007;334: 894-898.
2. Hebebrand J., Milos G., Wabitsch M., Teufel M., Führer D., Bühlmeier J., Libuda L, Ludwig C., Antel J. Clinical Trials Required to Assess Potential Benefits and Side Effects of Treatment of Patients With Anorexia Nervosa With Recombinant Human Leptin. Front Psychol. 2019;10:769.
3. Keski-Rahkonen A., Hoek H.W., Susser E.S., Linna M.S., Sihvola, E., et al. Epidemiology and course of anorexia nervosa in the community. American Journal of Psychiatry. 2017;164: 1259-1265.
4. Schorr M., Miller K.K. The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Rev Endocrinol. 2017;13: 174-186.
5. Hebebrand J., Albayrak O. Leptin treatment of patients with anorexia nervosa? The urgent need for initiation of clinical studies. European Child & Adolescent Psychiatry; New York. 2012, 21: 63-6.
6. Solmi F., Downs J.L., Nicholls D.E. COVID-19 and eating disorders in young people. Lancet Child Adolesc Health. 2021;5: 316-318.
7. Tyszkiewicz-Nwafor M., Adipocytokiny i objawy psychopatologiczne u pacjentek z jadłowstrętem psychicznym [online]. 2012. [dostęp: 29 październik 2021]. Dostępny w Internecie: http://www.wbc.poznan.pl/Content/245836/PDF/index.pdf
8. Mechanick J.I., Zhao S., Garvey W.T. The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice. J Am Coll Cardiol. 2016; 68: 1785-1803.
9. Coelho M., Oliveira T., Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9: 191-200.
10. Karageorgiou V., Furukawa T.A., Tsigkaropoulou E., Karavia A., Gournellis R., Soureti A., Bellos I., Douzenis A., Michopoulos I. Adipokines in anorexia nervosa: a systematic review and metaanalysis, Psychoneuroendocrinology. 2020, 112: 104485
11. Somogyi V., Gyorffy A., Scalise T., Kiss D., Goszleth G., Bartha T., Zsarnovszky A. Endocrine factors in the hypothalamic regulation of food intake in females: A review of the physiologicalroles and interactions of ghrelin, leptin, thyroid hormones, oestrogen and insulin. Nutrition Research Reviews. 2011; 24: 132-154. 2011; 24: 132-154.
12. Hebebrand J., Muller T., Holtkamp K. et al. The role of leptin in anorexia nervosa: clinical implications. Mol Psychiatry. 2007; 12: 23–35.
13. Gruzdeva O., Borodkina D., Uchasova E., Dyleva Y., Barbarash O. Leptin resistance: underlying mechanisms and diagnosis. Diabetes Metab Syndr Obes. 2019; 12:191-198.
14. Yeung A.Y., Tadi P. Physiology, Obesity Neurohormonal Appetite And Satiety Control. [Updated 2020 Nov 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK555906/
15. Francisco V, Pino J, Campos-Cabaleiro V, et al. Obesity, Fat Mass and Immune System: Role for Leptin. Front Physiol. 2018;9:640.
16. Sienkiewicz E., Magkos F., Aronis K., Brinkoetter M., Chamberland J., Chou S., Arampatzi K., Gao C., Konaris A., Mantzoros C. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism: clinical and experimental. 2011. 60. 1211-21.
17. Wauman J, Zabeau L, Tavernier J. The Leptin Receptor Complex: Heavier Than Expected?. Front Endocrinol (Lausanne). 2017;8:30.
18. Milos, G., Antel, J., Kaufmann, LK. et al. Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Transl Psychiatry. 2020(10):303.
19. Schorr M, Klibanski A. Anorexia Nervosa and Bone. Current Opinion in Endocrine and Metabolic Research. 2018 Dec;3:74-82.
20. Fraga Á., Carreira M., Izquierdo A., Dieguez C., López M., Gutierrez E. Temperature but not leptin prevents semi-starvation induced hyperactivity in rats: implications for anorexia nervosa treatment. Scientific Reports. 2020. 21. Yamada, Yamada-Goto, Nobuko & Katsuura, Goro & Ochi, Yukari & Ebihara, Ken & Kusakabe, Toru & Hosoda, Kiminori & Nakao, Kazuwa. Impaired CNS Leptin Action Is Implicated in Depression Associated with Obesity. Endocrinology. 2011.152. 2634-43. 10.1210/en.2011-0004.
21. Oral E., Gorden P., Cochran E., et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64(3):500-511.
22. Fiorenza C., Chou S., Mantzoros C. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011; 7:137-150.
23. Chou K., Perry CM. Metreleptin: first global approval. Drugs. 2013; 73:989-97.
24. Huvenne H., Dubern B., Clément K., Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obes Facts. 2016; 9:158-173.
25. Hainerová I., Lebl J. Treatment options for children with monogenic forms of obesity. World Rev Nutr Diet. 2013; 106:105-12.
26. Kühnen P., Wiegand S., Biebermann H. Pharmacological treatment strategies for patients with monogenic obesity. Journal of Pediatric Endocrinology and Metabolism. 2020; 33: 967-973.
27. Quennell J., Howell C., Roa J., Augustine R., Grattan D., Anderson G. Leptin deficiency and diet-induced obesity reduce hypothalamic kisspeptin expression in mice. Endocrinology. 2011; 152:1541-50.
28. Paz-Filho G., Wong M., Licinio J. The procognitive effects of leptin in the brain and their clinical implications. Int J Clin Pract. 2010, 64: 1808-1812.
29. Swieten M., Pandit R., Adan R., Plasse G. The neuroanatomical function of leptin in the hypothalamus. J Chem Neuroanat. 2014; 61-62:207-20.
30. Welt C., Chan J., Bullen J., Murphy R., Smith P., DePaoli A., Karalis A., Mantzoros C. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351: 987-97.
31. Chou S., Chamberland J., Liu X., Matarese G., Gao C., Stefanakis R., Brinkoetter MT., Gong H., Arampatzi K., Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011;108: 6585-90.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
